Stone Pharmaceuticals Innovation: Subsidiary SYS6010 initiates Phase III clinical trial.

Shiyao Innovation announced that its holding subsidiary, Shiyao Group Jiushi Biopharmaceutical Co., Ltd., recently initiated a randomized, open, multicenter, Phase III clinical trial of SYS6010 in combination with Enalor Sumab for first-line treatment of locally advanced or metastatic non-small cell lung cancer with driver gene-negative PD-L1 positive.